Evaluation of the effect of medlar fruit molasses on blood glucose control in children and adolescents with type 1 diabetes

Evaluation of the effect of medlar fruit molasses (Mespilus germanica L.) on blood glucose control in children and adolescents with type 1 diabetes - A randomized clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160913029802N3

Enrollment

Registered

2021-12-07

Start date

2021-11-11

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes. Type 1 diabetes mellitus

Interventions

Intervention 1: Intervention group A: After randomization allocation, in the first 45 days, group A receives a certain amount of medlar fruit molasses (the dose is determined based on the total phenol

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: The age group of patients is between 5-18 years. Children and adolescents with poorly controlled type 1 diabetes (HbA1c=8). The consent of the patient and parents to participate in the study has been obtained.

Exclusion criteria

Exclusion criteria: Patients with syndromic disorders (such as Down syndrome, etc.) Presence of renal failure in the patient (GFR <30) Taking drugs that affect blood sugar levels (lowering blood sugar such as metformin and raising blood sugar such as corticosteroids)

Design outcomes

Primary

Measure	Time frame
C-Peptide. Timepoint: To determine the level of C-Peptide in patients, a blood sample is taken from the patient on an empty stomach and at intervals of 30, 60, 90 and 120 minutes after consuming a mixture of liquid (containing 50% carbohydrates, 30% fat and 20% protein with a standard concentration of 6 ml per kg, up to 360 ml). Method of measurement: ELIZA Reader.;HbA1c. Timepoint: HbA1c (using Biroex kit) is measured at the beginning of the study, day 45 (group switching time) and the end of the study, in the laboratory of Bu-Ali Sina Hospital in Sari. Method of measurement: Hemoglobin A1c analyzer.	—

Measure

Time frame

C-Peptide. Timepoint: To determine the level of C-Peptide in patients, a blood sample is taken from the patient on an empty stomach and at intervals of 30, 60, 90 and 120 minutes after consuming a mixture of liquid (containing 50% carbohydrates, 30% fat and 20% protein with a standard concentration of 6 ml per kg, up to 360 ml). Method of measurement: ELIZA Reader.;HbA1c. Timepoint: HbA1c (using Biroex kit) is measured at the beginning of the study, day 45 (group switching time) and the end of the study, in the laboratory of Bu-Ali Sina Hospital in Sari. Method of measurement: Hemoglobin A1c analyzer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Shahani

Mazandaran University of Medical Sciences

so.shahani@yahoo.com+98 11 3354 3761

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026